The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
First-in-human phase I clinical trial of RSO-021, a first-in class covalent inhibitor of mitochondrial peroxiredoxin 3 (PRX3), in patients with malignant pleural effusion due to mesothelioma and other advanced solid tumors (MITOPE).
 
Dean Anthony Fennell
Honoraria - AstraZeneca; Bayer; Boehringer Ingelheim; Boehringer Ingelheim; Bristol Myers Squibb; RS Oncology (Inst)
Consulting or Advisory Role - Bristol-Myers Squibb; RS Oncology
Speakers' Bureau - BMS; Boehringer Ingelheim
Research Funding - Astex Pharmaceuticals (Inst); Bayer (Inst); BerGenBio (Inst); Boehringer Ingelheim (Inst); Bristol Myers Squibb (Inst); Clovis Oncology (Inst); GlaxoSmithKline (Inst); Iovance Biotherapeutics (Inst); MSD Oncology (Inst); Owkin (Inst); Roche UK (Inst); RS Oncology (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Janssen Oncology; RS Oncology
 
Sean Dulloo
Consulting or Advisory Role - RS Oncology
Speakers' Bureau - Advanced Accelerator; AstraZeneca; Chugai Pharma; RS Oncology
Travel, Accommodations, Expenses - RS Oncology; SERVIER
 
Simon Lord
Stock and Other Ownership Interests - Mitox Therapeutics
Honoraria - Eisai; Pfizer; Prosigna; Roche
Consulting or Advisory Role - Rejuversen AG; Sanofi; Shionogi
Research Funding - Pathios Therapeutics
Travel, Accommodations, Expenses - Roche
 
Fiona Thistlethwaite
Honoraria - Bayer
Consulting or Advisory Role - Bristol-Myers Squibb; Enara Bio; GlaxoSmithKline; Guidepoint Pharmacy; Immatics; Ixaka; Janssen; Leucid Bio; Pfizer (Inst); Scenic Biotech; T-Knife
Research Funding - 3-V Biosciences (Inst); Abbvie (Inst); Actuate Therapeutics (Inst); Adaptimmune (Inst); Adaptimmune (Inst); Agalimmune (Inst); AstraZeneca (Inst); AVEO (Inst); Bayer (Inst); BerGenBio (Inst); Blueprint Medicines (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Carrick Therapeutics (Inst); CytomX Therapeutics (Inst); Eisai (Inst); GenMab (Inst); GlaxoSmithKline (Inst); GlaxoSmithKline (Inst); Ignyta (Inst); Immutep (Inst); Incyte (Inst); Janssen (Inst); kinex (Inst); Lilly (Inst); Macrogenics (Inst); MedImmune (Inst); Merck (Inst); Millenium Pharamceuticals (Inst); MSD (Inst); Novartis (Inst); Octimet (Inst); Orion (Inst); Pfizer (Inst); Redx Pharma (Inst); Roche (Inst); Roche (Inst); Sierra Oncology (Inst); Synthon (Inst); Takeda (Inst); Tarveda Therapeutics (Inst)
Travel, Accommodations, Expenses - Ixaka; Scenic Biotech
Other Relationship - iMatch
 
Kevin G Blyth
Honoraria - Bristol-Myers Squibb; Lilly
Research Funding - RS Oncology (Inst)
 
Peter Wojciech Szlosarek
Honoraria - Boehringer Ingelheim; Bristol-Myers Squibb; Merck KGaA; Merck Sharp & Dohme; Roche
Research Funding - Polaris
 
Nick Maskell
Honoraria - BD Medical; Cook Medical
Consulting or Advisory Role - BD Medical
Research Funding - Becton Dickinson; Rocket Medical
 
Sanjay Popat
Honoraria - Amgen; AstraZeneca; Bayer; Bristol-Myers Squibb; Guardant Health; Janssen; Lilly; Merck KGaA; Novocure; Roche; Takeda
Consulting or Advisory Role - Amgen; AstraZeneca; Bayer; Blueprint Medicines; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo; EQRx; GlaxoSmithKline; Guardant Health; IO Biotech; Janssen; Lilly; Merck KGaA; MSD; Novartis; Pfizer; Pfizer; Pierre Fabre; Roche; Sanofi; Takeda; Turning Point Therapeutics
Research Funding - Amgen (Inst); ARIAD (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Clovis Oncology (Inst); Daiichi Sankyo (Inst); Epizyme (Inst); GlaxoSmithKline (Inst); Guardant Health (Inst); Janssen (Inst); Lilly (Inst); Mirati Therapeutics (Inst); MSD (Inst); Novartis (Inst); Roche (Inst); Takeda (Inst); Trizell (Inst); Turning Point Therapeutics (Inst)
 
Avinash Aujayeb
No Relationships to Disclose
 
Burak Y Aktas
No Relationships to Disclose
 
Sohail Rooman Javed
No Relationships to Disclose
 
Julio Herrero Colomina
No Relationships to Disclose
 
Brian Cunniff
Leadership - RS Oncology
Stock and Other Ownership Interests - RS Oncology
Consulting or Advisory Role - RS Oncology
Research Funding - RS Oncology
Patents, Royalties, Other Intellectual Property - RS Oncology
Travel, Accommodations, Expenses - RS Oncology
 
Jarrett Duncan
Employment - RS Oncology
Leadership - RS Oncology
Stock and Other Ownership Interests - RS Oncology
 
Philippa Graham
Employment - Bexon Clinical Consulting; RS Oncology
Consulting or Advisory Role - BioNTech SE; iTEOS Therapeutics
Travel, Accommodations, Expenses - Bexon Clinical Consulting; RS Oncology
 
Alice Susannah Bexon
Employment - Bexon Clinical Consulting
Leadership - March Biosciences; Sapience Therapeutics; Vyriad
Stock and Other Ownership Interests - AI Proteins, Inc; Sapience Therapeutics; Vyriad
Consulting or Advisory Role - March Biosciences; RS Oncology; Sapience Therapeutics; Vyriad
Patents, Royalties, Other Intellectual Property - Patent for AST-008 use in combination with checkpoint inhibitors; Patent for methods of treating cancer with combination therapy (Merck KGaA/PFizer/Vyriad); Patents for Sapience know-how relative to ST101
Travel, Accommodations, Expenses - RS Oncology; Sapience Therapeutics; Vyriad
 
George N Naumov
Employment - RS Oncology
Leadership - RS Oncology
Stock and Other Ownership Interests - RS Oncology
 
James F. Spicer
Stock and Other Ownership Interests - Epsilogen
Consulting or Advisory Role - Apobec Discovery (Inst); AstraZeneca (Inst); Avacta Life Sciences (Inst); Roche (Inst)
Research Funding - Achilles Therapeutics (Inst); BerGenBio (Inst); BluPrint Oncology (Inst); Bristol-Myers Squibb (Inst); Genmab (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); IO Biotech (Inst); Roche (Inst); RS Oncology (Inst); Starpharma (Inst); Trizell (Inst)
Patents, Royalties, Other Intellectual Property - Use of IgE antibodies for treatment of cancer
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; Janssen